Companies that foster an environment that supports professional growth are more likely to thrive and successfully adopt digital innovation. Here are the 100 best places to work in Europe—and how they stay that way.

<p>Zoetis ranks 93 on Fortune 100 Best Companies to Work For – Europe 2026 list.</p>

Fortune 100 Best Companies To Work For – Europe

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Zoetis

The business of veterinary care technology is both a lucrative and an impactful one—animal health company Zoetis brought in $7.8 billion in revenue in 2021 while developing vaccines and treatments for livestock and pets. Zoetis’s geographic footprint is as wide as its technological scope; the company oversees the production of veterinary biodevices and genetic tests from their design to manufacturing while providing services and products to over one hundred countries. In 2017, Zoetis launched its African Livestock Productivity and Health Advancement (ALPHA) Initiative with a grant from the Bill &amp; Melinda Gates Foundation; ALPHA now provides veterinary technology and training resources to veterinarians and farmers in sub-Saharan Africa. The effort addresses food insecurity by giving small farmers the resources and training to sustainably keep livestock healthy. ALPHA currently operates 16 serology labs across Uganda, Nigeria, Tanzania, and Ethiopia. So far, 11 million chickens and over 45,000 cows have been tested for diseases through these labs. Even more important is the educational element of the initiative: In all, 26,000 farmers and veterinarians have been trained in livestock care and an estimated 1.3 million people have been reached through train-the-trainer programs. That education includes “an emphasis on training women,” senior director of sustainability and innovation communications Christina Lood told <em>Fortune</em>. The Zoetis Foundation has also recently focused on empowering America’s small-business dairy farmers to utilize sustainable technology.

Change the World

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-431-Zoetis

The drug company, which was spun off from Pfizer in 2013, bills itself as the world's leading animal health company, producing medicine and vaccinations for pets and livestock. Those businesses proved relatively pandemic-proof in 2020, as Zoetis's revenue and profit grew by 7% and 9%, respectively.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-472-Zoetis

Zoetis develops and manufactures animal-health medicines and vaccines whose customers include veterinarians, pet owners, and livestock farmers.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Change The World

Impact Segment

Sector

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Companies To Work For Europe

CEO/Top executive

Group headquarters

HQ location

Certified countries

Woman CEO

Number of Years on List

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Get insights into Zoetis including business profile, stock information, news, and rankings from Fortune.

Zoetis (ZTS): Company Profile, Stock Price, News, Rankings

legacy

Zoetis

zoetis

Welcome to the Third Quarter 2026 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Mathieu Aussermeier, Senior Vice President, Corporate Finance for Zoetis. Presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forward automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. Instructions will be given at that time.

It is now my pleasure to turn the call over to Mathieu Aussermeier. You may begin.

Thank you, operator. Good morning, everyone, and welcome to the Zoetis third quarter 2026 earnings call. I am joined today by Kristin Peck, Chief Executive Officer, and Jay Saccaro, Chief Financial Officer and Chief Operating Officer. This morning, we issued a press release announcing our third quarter 2026 financial results. Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website, and that many of our statements today may be considered forward-looking statements, and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our company's Exchange Act reports filed with the SEC. Additionally, today's remarks will include certain non-GAAP financial measures.

Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures can be found in our earnings press release and our company's 8-K filing dated today, November 5th, 2026. We will also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impact Zoetis' growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance.

With that, I will turn the call over to Kristin. Kristin?

Thank you, Mathieu. Good morning, everyone, and thank you for joining us. Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations. Our diversified portfolio provided some resilience, and we focused on defending leadership positions with investments in key franchises. At the same time, we continued advancing the portfolio and innovation pipeline. While challenging dynamics are continuing, we are seeing progress in the actions we are taking and have narrowed our full-year revenue guidance to the high end of our range. As I walk you through our performance, I want to put the industry and company results in perspective and outline how we are positioning Zoetis for the near and long term. But first, I am pleased to welcome Jay to his first earnings call with Zoetis.

He brings a strong track record and a valuable combination of financial and operating experience, and we're excited to have him on the team. With that, let me start with what we see across the industry. As you all know, animal health remains a long-term secular growth industry, driven by a growing global population looking to eat more protein and adopt and care for more pets. Like most industries, however, animal health is not immune to cyclical factors, which affect pet care and livestock differently. In developed pet care markets, veterinary service costs have risen 50% since 2022, well ahead of general inflation. Alongside softer consumer confidence, that cost pressure is making pet owners more value-conscious and deliberate when making trade-offs to care for their pets. The mix of pets is also changing.

High housing costs are affecting homeownership and pet adoption, with fewer dogs joining households as cat ownership continues to grow. Because dogs are more medicalized than cats, this shift also affects underlying demand for veterinary services. These pressures are reflected in the continued weakness in U.S. clinic visits, which are down 3% year to date across categories. These dynamics, combined with intense competition in key franchises, continue to weigh on our companion animal revenue this quarter. At the same time, the bond between people and their pets remains strong. In the U.S., the Human Animal Bond Research Institute's latest survey found that 98% of pet owners experience health benefits from their pets, and 91% said knowing about those benefits makes them more likely to maintain their pet's health. That enduring bond is an important foundation for our industry, but it exists alongside real barriers.

37% of people planning to get a pet cited the cost of ownership as a concern. As the industry leader, we are focused on meeting customers where they are. That means working with veterinary practices to support their profitability and success while developing programs to help pet owners manage the cost of care. In contrast, livestock is benefiting from growing demand for quality protein sources. We're also seeing growing demand on animal health to improve productivity, support food security, and adopt a One Health approach. That demand has contributed to historic industry growth, and for Zoetis, underscores the strength of a broad and diverse portfolio. While we expect livestock to remain a strong contributor over the short, medium, and long term, disease, weather, and local production cycles will continue to influence year-to-year results. Diversity matters, not only across species, but across geographies.

Growth conditions vary significantly from market to market, reflecting differences in economic and geopolitical conditions, species mix, and regulatory environment. In many developed markets, pet care represents a larger and more medicalized share of the animal health market, while in many emerging markets, livestock does. As a result, the same economic shifts can affect markets in very different ways. Tariffs and trade flows continue to evolve, and our commercial strategies reflect the conditions in each market. That local focus matters because emerging markets are expected to remain the fastest-growing part of animal health, with room to bring more animals into regular care, gain share, and broaden access to innovation. Which brings me to what we're doing to defend and grow our leadership.

Building on the actions we've outlined over the past two quarters, today, I'll focus on three priorities: leveraging the diversity of our portfolio, expanding access to established franchises, and advancing innovation. I'll take you through each with examples of how they're showing up across our key franchises. First, we're leveraging the advantage that comes from the diversity and differentiation of our portfolio. Competition is increasingly playing out product by product, but our range of options within the therapeutic categories and across channels gives us more ways to meet customer needs and compete effectively. Those choices are especially important in our key dermatology franchise, where share pressure is most acute. We are continuing to sharpen commercial execution, directing resources where they can influence customer decisions, and reinforcing the value of our differentiated portfolio with vets and pet owners.

For example, we're using that breadth to drive conversion to Apoquel Chew with chew in the room promotion and in-clinic sampling, highlighting a more convenient alternative that can support treatment compliance. At the same time, we expect U.S. approval of long-acting Cytopoint in the fourth quarter, adding a more convenient option for chronic itch, a segment that accounts for more than 60% of global dermatology doses. We're using that added diversity to build awareness for the next option in derm, with a teaser campaign ahead of approval. Similarly, since the beginning of the year, we faced mounting generic competition for Convenia and Cerenia. We acted swiftly, and this quarter, we saw the pace of share gains moderate for the first time since entry.

With recent FDA approval in the U.S. and its coming launch in Canada, Convenia RTU for dogs extends the portfolio with a single injection that can provide up to 14 days of treatment. Second, we're expanding access to our established franchises and investing in the evidence and medical support that help vets navigate a more selective market. When visits are down and owners are weighing the cost of care, the clinical conversation matters. Veterinarians need to identify patients who can benefit and have relevant evidence to support treatment decisions. This is a central role of medical affairs, and one reason we launched the Medical Hub, which houses our scientific insights, publications, and educational materials in one place for veterinary teams. That approach is relevant in parasiticides, where softer end market demand is creating pressure.

Even with double-digit declines in U.S. flea, tick, and heartworm clinic visits, the Simparica franchise delivered modest growth this quarter, as expanded access to Simparica Trio drove growth internationally. Trio's triple combination protection gives vets a differentiated option, supported by recent peer-reviewed research on heartworm resistance. One example of scientific evidence supporting the franchise is a recent peer-reviewed speed of kill study available through the Medical Hub, and our continued investments in phase IV studies provides vets with relevant evidence in a more selective market. We also now expect approval of Simparica Duo by year-end, ahead of our original timeline, broadening the portfolio and extending access to customers with unmet needs. This same strategy applies to OA pain. We're building the category, but it requires sustained effort to improve disease awareness and help veterinarians identify more patients who could benefit from treatment.

We are clear-eyed about the work ahead and measured in our expectations. At the same time, just four years ago, alternatives to NSAIDs were limited. Today, our portfolio offers dogs and cats monthly or longer-acting three-month pain relief. Recent approvals and launches of Lenivia and Portela extend those options, and we believe broader access will build the category over time. These are strong franchises in markets we help build. Our focus is to support customers through current pressures while continuing to invest in their growth. Third, we continue to advance innovation while remaining disciplined in how we allocate capital. In this environment, that means taking costs out where needed to operate more efficiently while protecting investments in innovation and advancing our robust pipeline. Lifecycle innovation is central to the first.

The examples I have discussed in derm, paras, and OA pain strengthen established franchises and help create resilience in a pressured market. We are applying this same approach to livestock through new formulations and expanded indications across the portfolio, including FDA emergency use authorization of Dectomax for New World screwworm. These extensions help keep our portfolio relevant to evolving customer needs and support franchise contribution over time.

Last year, at our innovation webcast, we committed to achieving a significant major market approval every year for the next several years. To date, we have met our 2026 milestones, and in some areas, moved ahead of schedule. For example, Convenia RTU has now received approvals in two major markets, both earlier than planned. Beyond lifecycle innovation, we are working to create new categories in areas such as renal disease, oncology, cardiology, and obesity, where diagnosis is essential to identifying patients who may benefit from treatment.

That makes diagnostics a strategic enabler of this pipeline. Our investments are building the tools and capabilities to support that work. This quarter, companion animal diagnostics delivered double-digit revenue growth, reflecting increased utilization and contributions from the strategic acquisitions of VitalRADS and VPG. Our market leadership was built on innovation. Sustaining it means extending the franchises we have today while building the capabilities that will enable the future of animal health. Before I turn it over to Jay, I want to be clear that while the companion animal market remains soft in the quarter, Zoetis' targeted commercial execution has helped mitigate the macro and competitive pressures, and we will continue to adapt our approach as the market evolves.

We remain focused on disciplined resource allocation paired with investments to grow markets and share. At Zoetis, that means directing resources to defend our key franchises today while advancing innovation for the future to drive strong growth over time. We have the portfolio, science, and customer relationships to do just that.

With that, I am pleased to hand it over to Jay.

Thanks, Kristin. I am excited to be here for my first earnings call with Zoetis. While I am just a few months in, my conviction in this company has only grown. The product and organization are world-class, and the innovation pipeline spanning CKD, oncology, and next-generation lifecycle products represents a real catalyst for long-term value creation. My near-term focus is on understanding our business and operations in detail, ensuring our cost structure is as competitive as our portfolio, and working alongside Kristin and the team to navigate the current market environment with discipline and transparency. As I deepen my understanding of the business, we will also be evaluating the financial metrics we share related to guidance, and we look forward to sharing an update with you on the fourth quarter call. With that, let's look at the quarter.

We delivered revenue of $2.4 billion, declining 1% on both a reported and organic operational basis, in line with our expectations, driven by a 1% price decline and flat volume. Our U.S. segment revenue was $1.2 billion, down 6%, driven by declines in companion animal from our key dermatology portfolio, as well as the impact of generics on certain brands, while our international segment was $1.1 billion, up 4%, with growth across livestock, parasiticides, and OA pain more than offsetting dermatology headwinds. We delivered adjusted EPS of $1.75 in the quarter, up 1%, driven by the lower share count due to our ongoing share repurchase activity. Adjusted gross margin was 71%, down 30 basis points on a reported basis. Foreign exchange had a favorable impact of 30 basis points.

On an operational basis, gross margin was down 60 basis points, driven by the impact of our strategic pricing initiatives, product mix, and certain inventory-related charges, partially offset by refunds related to prior tariff assessments. Adjusted operating expenses were $749 million, flat operationally, with both adjusted SG&A of $571 million and adjusted R&D of $174 million also flat, reflecting the continued benefit of our cost and productivity programs, including lower incentive compensation and professional services savings, partially offset by increased R&D investments in data and digital initiatives and our broader project portfolio. Adjusted net income was $720 million, down 7% on an organic operational basis. You will see that our GAAP results also included $78 million of an impairment charge on previously acquired in-process research and development assets, resulting from updated estimates of development and commercial assumptions.

Let's look more closely at the key drivers of our revenue performance this quarter, starting with companion animal, where globally we declined 5% on $1.6 billion in revenue, driven by an 8% decline in the U.S. and flat performance internationally. Within companion animal, our performance was driven by key dermatology, which declined 16% globally on $396 million in sales, reflecting competitive headwinds and pricing actions across both segments. In the U.S., we declined 13% in the quarter on $266 million in revenue, driven by share loss in Apoquel, which was slowed by our promotional investments, partially offset by volume growth in the chewable formulation, which now represents roughly half of total Apoquel volume. Cytopoint sales also declined, reflecting canine visit declines of approximately 5% in the quarter, with pruritic visits specifically down 3%, as well as broader affordability pressures on pet owner spending.

Direct competitive impact from new launches in the injectable dermatology space were minimal. Internationally, key dermatology was $130 million, down 20%, with pressure most acute in Europe, where new entrants drove volume losses across the Apoquel franchise. Cytopoint proved more resilient, given its differentiation in international markets. In addition to declines in key dermatology, generic competition in Cerenia and Convenia continued to pressure U.S. results. While volume declines moderated to their lowest level since generics entered the market in Q1, we continue to manage through a challenging competitive dynamic. Partially offsetting these declines, our Simparica franchise grew 1% on global revenue of $358 million. The results were mixed across our segments.

Internationally, we grew 10% on revenue of $99 million, driven by strong Simparica Trio momentum across Europe and Latin America, partially offset by expected erosion in Simparica as customers continue transitioning to the triple combination product. In the U.S., the franchise declined 2% on $259 million in revenue, as accelerating declines in flea, tick, and heartworm clinic visits were partially offset by volume gains from our cross-portfolio promotion. Our OA pain meds generated $137 million in sales, increasing 2% globally. We continue to see contributions from the launch of Lenivia and Portela in the EU and Canada, which drove 13% growth internationally on $86 million in revenue, with both products gaining traction quickly and early satisfaction scores from veterinarians and pet owners remaining exceptionally high. Meanwhile, in the U.S., OA pain meds contributed $51 million in total, declining 12%.

Lower OA visits and ongoing safety perception headwinds weighed on Librela adoption and daily sales trends, partially offset by Solensia's resilience, supported by stable patient share and increased feline clinic visits in the quarter. Companion animal diagnostics delivered $122 million in revenue, up 13% globally, with double-digit growth in both the U.S. and internationally. Growth was driven primarily by recent acquisitions in both segments, including VitalRADS in the U.S. and VPG in the U.K. and Ireland, with continued underlying adoption of our point-of-care and Imagyst platforms contributing to the remainder. Innovation across the diagnostics portfolio continues to advance, with OptiCell gaining traction in hematology and OmniMax, our next-generation point-of-care analyzer, on the horizon. Now, moving on to livestock, which delivered $797 million, up 7%, with contributions across both the U.S. and international.

U.S. livestock grew 5% on $266 million in revenue, supported by reliable Ceftiofur supply driving cattle performance, broad-based swine growth, and strong poultry vaccine demand. Internationally, we saw sales of $531 million and growth of 9%, led by cattle strength across the segment and outstanding fish performance, driven by higher vaccination rates in Norway. Our capital allocation priorities remain unchanged. We will continue to invest in R&D and internal innovation, the engine of our long-term growth, while remaining disciplined in pursuing bolt-on business development opportunities. After internal reinvestment and business development, excess capital is returned to shareholders, as demonstrated by the $2.4 billion distributed in 2026 through the third quarter in the form of both buybacks and dividends.

Now, turning to our updated full-year guidance for 2026. Q3 delivered in line with our expectations, giving us the confidence to update our full-year guidance range. We are narrowing our full-year revenue guidance to $9.22 billion-$9.32 billion, representing an organic operational decline of -2% to -1% year over year. We are raising our adjusted net income guidance to $2.6 billion-$2.64 billion, representing organic operational decline of -7% to -5%. We are also raising adjusted diluted EPS to $6.25 to $6.35.

To close, our diverse portfolio and disciplined commercial execution continue to help us navigate an operating environment shaped by competitive pressure in our key companion animal franchises, softer clinic visits, and ongoing affordability headwinds for pet owners. But we are also seeing strength in livestock and solid momentum in diagnostics. Before I turn it over to the operator, I wanted to share a brief word on 2027. While it is too early to provide specific guidance, we will plan prudently for the upcoming year. We will not be assuming improvements in the macro environment or pet owner spending trends, and we expect the competitive dynamics we have mentioned to remain a factor throughout most of the year.

At the same time, we are encouraged by the commercial strategies we are executing, and most importantly, we are excited about the innovations planned for 2027 and 2028. While we expect limited revenue contribution from these launches in 2027, their impact should build later in the year and into 2028. We look forward to sharing more about this on our Q4 call. Our focus remains on executing with discipline and positioning the business for improved performance over time.

With that, I will turn it over to the operator for questions. Operator?

Thank you. If you would like to ask a question at this time, please press star one on your telephone keypad. If at any point your question has been answered, you may remove yourself from the queue by pressing star two. In the interest of time, we ask that you limit yourself to one question and one follow-up. When posing your question, please pick up your handset to allow optimal sound quality. Our first question is coming from Chris Schott with JPMorgan. Please go ahead. Your line is open.

Thanks so much for the questions. I guess the first one for me would be great just to get additional color on the impact the promotional activities you initiated this year are having on the business. I guess specifically, I am just trying to get my hands around what areas do these seem to be gaining traction, and are there areas where you have not yet seen an impact? My second question was just maybe building on some of those 2027 comments that you just made. Just as you think about the various pushes and pulls, are just there any other considerations we should be keeping in mind for next year's numbers? Trying to get my hands around directionally, do you see the street in the right place with both top line and EPS currently? Thanks so much.

Great. Thanks, Chris. I will take your first question. I will let Jay take your second. As we spoke about on our last few calls, our pricing strategy is really focused on retaining volume and gaining share, and it is really focused on deliberate, analytically supported actions that are protecting list price, but really focusing on gross-to-net investments. We were quite pleased with the performance of those investments in the quarter, specifically, and some of these facts are in our slides that we shared as well. The promotional defense on derm managed to slow U.S. dermatology share loss in the quarter to 4 points in Q3. It was about 7 points in Q2 overall in derm. So, really pleased with really slowing that overall decline in share loss there.

As you think about how they came through in our parasiticides, we are really pleased that we held share in the quarter with Simparica Trio at a 22.5% share, and we remain the market leader in puppies, which I think is a really important future prediction of sales there. So, we were very pleased. Again, we are going to stay focused and continue to watch the market as it evolves, and make sure we are targeting our investments to make sure we continue to protect share and ultimately grow it.

Sure. So, look, we are in the middle of our budgeting process as we speak, so it is definitely too early to comment very specifically about 2027, but we did want to share some guiding principles. I think from our perspective, as we approach 2027, we are going to be conservative or prudent as we put together our numbers. We have seen some macro trends over the last several quarters. We are not going to assume a market change in macro factors. We have seen some competitive dynamics, and while I think we walk away from the third quarter encouraged by the activity from a promotional and commercial standpoint, at the same time, we are not going to assume a change in competitive dynamic in 2027.

Then, finally, as I come into the role here, one of the things I have spent a lot of time on is the R&D pipeline. It is incredibly exciting the work that our teams are doing, and the impact over time is going to be substantial. At the same time, it is not going to have a huge impact in 2027. So, from our perspective, we are going to be very thoughtful as we put together our plan for 2027. I am hesitant to comment on street models or anything like that, certainly at this point. We are very excited about the long-term prospects that we have, but we are going to be clear-eyed as we approach 2027.

Thank you. Our next question comes from David Westenberg with Piper Sandler. Please go ahead.

Thank you so much. We followed parasiticides for a while from topicals, the orals, isoxazoline. There has generally been a consistent pattern that a new product will come in, it will get some new generational starts, and then the market kind of matures and normalizes. We saw this when you launched Simparica. Originally, you did take share, but NexGard kind of settled in and kind of continued to grow. Is that what we think we could see in the 2027, 2028 market with Simparica, with some of the new entrants and new categories? What would make it different, and what kind of indicators would tell you that maybe growth would normalize in that category in 2027, 2028? Again, I do not want to take away, you did grow 5% in Simparica Trio overall, but just curious on that, and I will have a follow-up.

Sure, Dave. I will take that first question before your follow-up. As I said, we were pleased with the performance of Simparica in the quarter. The franchise globally did about 1%. We did about 4% growth in Trio specifically. As I was just talking about, we are very pleased that in the U.S., we are the market leader and we maintained our share at 22.5%, which is almost two times our next biggest competitor. I also think it is important if you think about parasiticides, just like the U.S. from international, we are seeing significantly higher growth in international overall. I think you are seeing this because triple combination category is still in its infancy there.

We are really expanding and entering new markets, so we see Trio is still early in its penetration, and we believe there is really a long runway for growth there. We are continuing to invest in innovation in this space. As we also mentioned, we are expecting approval of Simparica Duo by year end, which is ahead of its original timeline. I think this will continue to broaden our portfolio. I guess the way we see the market, we think there is still significant opportunity to continue to expand this market from single combinations, from topicals and collars, into triple combination, as well as to gain share. We have a very comprehensive portfolio that we think is differentiated, and we will continue to invest there.

I will maybe move to your second question.

Sure. Cytopoint, as you noted, has held in well. There isn't anything in the market like it right now. Befrena does have a label of four to eight weeks efficacy, looks pretty competitive as it launches in 2027. Can you walk us through both first, maybe from a defensive strategy perspective early on, and then maybe from an offensive strategy as you get your own long-acting product? Can you confirm that long-acting is still on time? I think you said Q4, you do expect approval. How fast is that to roll out? Thank you so much for taking the questions.

Sure. Thanks. We continue to believe that Cytopoint and the long-acting space in derm is really exciting. As we mentioned, it did fare better in the quarter. I think that's really because the customers are on it are quite pleased with the efficacy of the product overall. As you know, we did have a new entrant in that category in the U.S. To date, they've had limited share given their supply challenges. What we are really excited about as we see in this category is to continue to expand it. We are expecting the approval of Cytopoint long-acting this year. We think Cytopoint will help us expand the category, honestly. It provides a more convenient option that lasts longer, which is really helpful for busy pet owners who coming in every month might be a challenge.

This is part of the Zoetis strategy to continue to innovate in each of our key therapeutic areas to both make sure that we can continue to grow our share, as well as expand the market overall. We're pleased to have that product, and we look forward to launching it in the first half of next year. We are on track with Cytopoint long-acting, and we think it'll be a great addition to continue to build this brand.

Thank you. We will move next with Jon Block with Stifel. Please go ahead. Your line is open.

Great. Thanks, guys. Good morning. Jay, I am arriving at an implied 4Q 2026 organic revenue growth rate of around -3%, off an easy comp. Maybe just your thoughts on that, if accurate, any color. Then maybe more importantly, what does this mean for the business looking forward? If you could give us some color there, then I will ask the follow-up.

Sure. I think as we think about the fourth quarter, it really is important to take it in the context of the third and fourth quarter and also the full year. On the first half, we were down about 1 point. The third quarter was down a bit more than that. As we look at the third and fourth quarter together, we are talking about a full year growth rate leading to a decline of -1% to -2%. We historically see some seasonality with higher sales in the third quarter and then the fourth quarter. In this particular case, with the promotional activity that we pursued in the third quarter, we are anticipating a third to fourth quarter decline in the high single-digit range.

Very much in line with our expectations, although I would say the market and our performance has been a little bit better than our anticipation. Related to that, we always anticipated a deceleration in the fourth quarter versus the third. As we think about what this means for the overall health of the business, it really is important to consider it in the context of the third quarter as well.

Okay, that is helpful. Thank you. Then, I guess just to pivot, livestock continues to be the bright spot, pardon me, for you guys. You might exit 2026, or pardon me, 2026 might have a comp of high single digits. Maybe if you could just give us some thoughts on sustainability of livestock. Kristin, you mentioned the protein tailwinds, and that does not look like it is going away anytime soon. But just looking forward for this business off a high single-digit comp that might add some screwworm tailwinds in there, how do we think about that for 2027 and beyond? Thank you.

Yeah. We were quite pleased with the performance of livestock in the quarter. It grew 7% overall, and really underlying that, as you mentioned, is demand for quality protein, and that's really across the globe, I would say. We saw U.S. delivering 5% to the quarter and international at 9% in the quarter. If you think about that, international livestock is a higher percentage of our business, as we've talked about, and that growth was really broad overall across species. We are confident that livestock will remain a strong contributor. Obviously, as we see, there's definitely a little more cyclicality historically in livestock. It's influenced by disease, by weather, by outbreaks, local production cycles overall. But there were a few years, obviously, as you recall, where Zoetis had an LOE, and we also had African swine fever outbreaks.

Historically, livestock is a solid contributor overall as an industry grower, and specifically for Zoetis, we're quite focused in our portfolio, as we've mentioned, around vaccines and genetics and preventatives, which we think has positioned us well as we see strong continued demand for protein.

Thank you. We will move next with Brandon Vazquez with William Blair. Please go ahead.

Hey, good morning. Thanks for taking the questions. Kristin, I wanted to follow up on your commentary about you guys have been pretty successful, it seems like, in defending share in some of the gross-to-net promotional activities, maybe for lack of a better phrase to use there. The question being, do you think that these gross-to-net promotional activities are short-term in nature? Is this something you're doing to combat kind of temporary entrants from competitors, or do you think on a go-forward basis that you'll need to keep this new gross-to-net? Part of the question is basically, what are the implications to your margins and your gross margins on a go-forward basis within the companion animal business?

Yeah, I mean, it's a great question. I think our focus right now is with a lot of new entrants in both derm and parasiticides. Historically, as you know, in our space, when new entrants came, they expanded the market. We aren't seeing that right now, and so we've had to be a little more focused on some of these gross-to-net investments. Ultimately, we think when share settles out, and historically you've seen that somewhere between 12 and 18 months, and what we're really watching for to know how to tweak, and we're constantly watching every month, but certainly every quarter, is how are we seeing those shares stabilize? When we see two quarters where those shares pretty much stayed, we'll have a sense that those shares have stabilized, and we can then really focus more on gaining share and growing the market overall.

I don't think these are here forever, but I think as Jay mentioned in his remarks, I think some of these new products have only recently entered in certain markets, and this is a market-specific investment. We think we need to lap those new entrants for both derm and paras to really have a sense of how to continue to adjust our gross-to-net investments. But I think our strategy, as I mentioned earlier, is making sure at the very least we defend our share, and we're focused on both growing share and growing these markets ultimately. The reality is there are still way more untreated animals in both of these categories than there are treated animals.

There's significant opportunity to do that, but I think as you combine both the competitive situation right now and macro, the market itself isn't growing as much, but we do continue to believe that that will happen ultimately as we get through this cycle.

Okay. On Lenivia, I just want to hit on that for a second because that feels like clearly one of the areas you guys are still kind of innovators and a fast leader there. Early days of Lenivia, I don't know how many pilot accounts you might be having, but any metrics, any anecdotal feedback you want to share with us just in terms of, is this the product you think through 2027 might be able to start to re-accelerate the OA pain management section? Thanks.

Yeah. We are quite excited on the performance of both Lenivia and Portela, which is the long-acting for cats. We have launched across a number of markets in the EU and Canada, and what we are hearing right now, again, I would like to be clear, this is obviously early days, but the veterinarian satisfaction is high at 97% for Lenivia and about 95% for Portela. Pet owner satisfaction is high at 98%. And what we are seeing is what we expected, which is that Lenivia and Portela are providing a really good opportunity to grow the market. Having a product that is more convenient, that is once every three months, has really helped expand the market.

Obviously, we have seen some cannibalization, as you saw, but as you looked overall at OA pain and international, we saw growth, and that is really been driven by Lenivia and Portela and sort of the positive both veterinarian and pet owner uptake of those products. We continue to expect approval of Lenivia in the U.S. in 2027, so we will be excited to bring that product to the U.S. as well.

Thank you. Our next question comes from Erin Wright with Morgan Stanley. Please go ahead.

Great. Thanks for taking my question. I am curious if you are seeing, and I will ask both mine upfront, but are you seeing continuing stabilization in the share loss through the fourth quarter, and should we anticipate any changes to the pricing and promotion strategy? You did a promotion in August, September. Seems like you feel okay with that. Do you double down? Are you doing more in terms of pricing or promotions on that front? And are you seeing also a competitive response, a lack of competitive response? You could potentially see stabilization quicker than expected.

My second question is more on margins and into next year, and what does this all mean from a margin standpoint, and what are maybe some of the mitigating factors we should consider on the cost side? Jay, as you look at this business and you think about some of those opportunities from an efficiency perspective, how do you think about that? Thanks.

Thanks, Erin. I'll take your first question, and I'll let Jay take your second. As we spoke about, we are pleased with the performance of the promotions. We are adjusting month by month, quarter by quarter with those plans. As I said, we're going to watch overall share and look for overall stabilization. But we also need to be cognizant of when new products will be entering or when supply will be expanding in some of these markets. So, although we're pleased to move from a negative seven to negative four as we talk about derm share loss overall from Q2 to Q3, our goal is to get that to zero and to be growing back, to be clear. So, we'll continue to watch that. We're pleased that we are slowing that decline right now.

Our goal, obviously, is to get that to stabilization on that share, and importantly, to get that stabilization to as high a share as we possibly can. We'll continue to look at the promos we think help drive that. We do like this focus on gross-to-net versus list, because it helps us make sure that we have clear outcomes to the programs that we run, clear metrics we can see that we're delivering. As we think about some of those overall programs, they're really focused on things like measuring new auto-ship starts, new patient starts, loyalty at the clinic. We'll continue to invest in those. We have obviously seen some competitive responses as we expect, but nothing that we weren't expecting overall. We'll continue to monitor it and provide an update as we get to Q4 on the continued strategy here.

Jay, do you want to take the second question?

Sure. Just overall, as we think about margins, the full year margin is shaping up in line or better than our expectations. We are pleased with the progress on both the competitive initiatives we put in place, but also the cost initiative. You will note SG&A declines 1% on an overall basis as we expect from an overall year standpoint. Now, it is important not to look at the fourth quarter in isolation. Some of the comments I made relative to revenue impact not only gross margin, but also impact SG&A leverage in the quarter. So, you have to look at it in a broader context, second half or even more broadly than that. Now, as we go to next year, there is a couple of drivers that we are going to be very focused on. First of all, we do have a world-class manufacturing and supply chain organization.

I have been really impressed with the work that that team is doing. The amount of manufacturing of product that we have done is just astounding. Using that as a competitive advantage, especially in this environment, I think can be really, really important to our success over time, but also in 2027. Secondly, I noted SG&A declines this year. As we look to next year, we will continue to focus on savings initiatives. We have opportunity. We have pursued some cost savings initiatives this year. We will have further impact from those next year. At the same time, we will continue to invest in R&D for success. I think one of the things I have walked away from over the last several months, the remarkable pipeline that we have in place. So, we are going to fund those initiatives for success.

There will be some benefit in 2027, but much more prominent 2028 and 2029. So, we will fund those for success, but really target gross margin and SG&A, or cost of goods and SG&A as areas where we focus our initiatives on.

Thank you. Our next question comes from Matt Dellatorre with Goldman Sachs. Please go ahead.

Great. Good morning, and thanks for the question. Maybe just on derm, if we look at the franchise sales decline, could you just help us break out how that splits between volume and some of the price gross-to-net promotions? Then, in the last quarter, you all highlighted that retail channel growth had moderated versus prior being more of an offset to some of the clinic weakness. Could you just give us an update there on what you're seeing, and if the outlook has improved at all? Thanks so much.

Sure. I'll let Jay take some of the specifics on the derm breakout you're looking on volume versus price, and then I can take the I'll start on the first one, and then Jay can take the one on derm. What we saw in the quarter overall is the retail sector, whether you think of both online and in-store, if you compare it to 2025, that growth has slowed. Home delivery, on the other hand, has been stronger as we looked at it. What we were very pleased with in the quarter that I think helped contribute to the defense of both Simparica and derm is real investments in retail, re-looking at our MAP pricing there, which I think has made us more has really strengthened us in the retail channel overall. So, we're continuing to invest there. a lot of pet owners find that quite convenient.

We're seeing advantages to compliance there overall. So, we'll continue to invest in that sector. I think overall, given it's had such strong number of years, that growth is slowing a little bit, with more of that getting made up more recently, as you think about home delivery. But I don't know if you want to take the question on derm.

Sure. So overall, as we think about the entire third quarter performance, we highlighted in our remarks earlier roughly flat volume with down 1% or so in price. Dermatology had a little bit more of a prominent impact than that from a pricing standpoint, but overall, the franchise was down 16%. Price contributed, and it was higher than the corporate average price decline, with volume down the lion's share of it, though. So really, that's the shape of the trajectory. As we think about the pricing changes, really, it was virtually all, in fact, it was all gross-to-net investments that we made versus any changes to list price across the portfolio of derm.

Thank you. Our next question comes from Navann Ty with BNP Paribas. Please go ahead.

Hi, good morning. Thanks for taking my question. Can you discuss further the international companion animal performance, which was flat this quarter? Have you seen more competitive or macro pressure there? Then in OA pain, if you could discuss cannibalization in the markets where you have launched Lenivia and Portela. Maybe my last question on the breakthrough innovation pipeline, if you are on track for the late 2027 approval. Thank you.

Sure. I will start on the first, and Jay, you can let me know if you have anything you want to build. We did see flat growth overall in international in the quarter. That really had to do with similar trends that you might have seen in some of the developed markets in Europe with pressure overall on derm. We did see strong growth overall in parasiticides there. I think some of the same sort of trends we have been seeing overall in markets where we have had new competitors entering. If you go market by market, obviously there, you have to see that the timing may obviously switch overall. I think your second question was on breakthrough innovation, I believe. We are very excited, as Jay said, around our innovation.

As we mentioned, we are committed to achieving a significant major market approval every year for the next several years. We were really pleased that all the milestones that we have outlined for 2026 are on track, and we have got a few that have moved forward. We will see a number of launches of some of these products into 2027. We will see those ramp as they go through the year, obviously. But also very excited, to your point, on the breakthrough innovation. Those are the creation of new categories, as we outlined in some of our slides. That is around conditions such as chronic kidney disease, cardiology, oncology, obesity, diabetes, anxiety. These are important new categories where there are very limited products out there today.

This is something that Zoetis has always been known for, really creating new categories and bringing innovation. We remain quite excited on all these. Importantly, we look forward to sharing a more comprehensive update to that pipeline at JPMorgan, where we will update all the sort of expectations as we look at the years to come.

Thank you. We will come up next with Christopher LoBianco with TD Cowen. Please go ahead.

Thanks for taking our question. We had two. First, can you quantify the impact of any one-time factors or one-offs in the quarter, like stocking or one-time purchases? Second, can you provide any color on the product profile of Simparica Duo? Is this product meant for RX or OTC usage? Thank you.

Sure. As it relates to one-time items, really in the third quarter, we did have the promotional activity that I commented on, and that really impacts the shape of sales growth between the third and fourth quarters. That is something that we periodically do. You will recall we have done these in past years. As we evaluate 2027, we will evaluate the appropriate promotional activity. But beyond that, which did sort of impact the sales contour between Q3 and Q4, there were really no one-time items to point out. Like I say, that is something that we will evaluate next year, what is the right shape of promotions as we go through the year. As it relates to the product profile-

Yeah. For Duo, we are quite excited to expect approval for Duo this year and launch it next year. It will be an RX product. It is not an over-the-counter product. It will be part of the Simparica family. The focus of this product is meeting an unmet need, which is, there are many areas of the country where there are fleas, ticks, and intestinal worms, but heartworm is not a major area, or areas where heartworm is huge and they want to move to our product ProHeart, and it really meets that need. So, it is a product really focused on fleas, tick, heartworm, and intestinal worms. So, we are excited to get approval there and then add this to our overall Simparica family.

Thank you. We will come up next with Andrea Alfonso with UBS. Please go ahead.

Yeah. Thank you so much for squeezing me in. My question was really, I appreciate all the color that you provided on sort of the competitive, depending on the competition by channel. I guess, any color on the efforts by channel? How does it vary between retail versus independents, and how do we think about the competitive intensity there? Then I guess separately, I will squeeze this in, is with two big distributors coming together imminently, how are you approaching distributor relationships versus more direct engagement with practices? Thank you so much.

Sure. I will take those questions as a comprehensive, because I think what you are really talking about overall is channel. I think, as we think, you have to pay attention to all those. Obviously, we have had a strength in the corporate side historically. We will continue to invest there. We think there is still a lot more that our teams are focused there on making sure if there is, if we are one of two, we want to be the largest there. So, there are very targeted promotions meeting each of those individual corporate strategies there. It is also focusing on independents. We have a loyalty program there that we are quite focused on. That is obviously part of our targeted promotions, as we talked about, is how do we gain share in some of those independents. So, we will be focused there.

We talked a lot about investing in retail, where you get an opportunity for auto-ship. There's really great movements as well in the box store side as well. These are all important. As we think about distribution, they've always been an important channel for us. Some of our customers prefer to place one order across all those. We're going to continue to and make sure that we're available wherever both the vet and the pet owner wants to access our products. We'll look at channels holistically and make sure we have a targeted strategy to meet each of those different channels' needs.

Thank you. We will move next with Steven Dechert with KeyBanc Capital Markets. Please go ahead.

Hey, thanks for the questions. I guess just on the gross-to-net investments on the vet clinic side, were you in the process of the product bundling with clinics? Have you mainly worked through all those contracts, and how often can you revisit those contracts for further changes? On key derm internationally, on their organic growth being down 20%, a little worse maybe than we expected. I guess Numelvi and Zenrelia have been in that market in Europe for a while, so I guess just maybe what changed this quarter with the competitive dynamic? Thanks.

Sure. Your first question on gross-to-net and product bundling. We have always had a broad portfolio. We have the broadest portfolio. We've always been able to leverage that portfolio as we think about overall promotions. We're going to continue to do that. As we think about some of those clinics, we look at our overall share there. We try to make sure that they're buying across our portfolio. I think that will remain, Steve, an important strategy for us. We're obviously seeing some competitors try to copy that where they can, but they don't have as broad a portfolio. Importantly, as we've talked about before, it's really the innovation that we bring that pulls this forward.

As we think about the approvals we had this year and all the launches we are going to have next year, I think that sets up that portfolio play that we are talking about. We look at each of those programs on a quarter-by-quarter basis. The contracts, as you think about some of the corporates, each contract is slightly different. Normally, there are two-to-three-year contracts, where you can obviously revisit those. But we are very pleased with how we are positioned there. Again, I think our innovation is what really differentiates us overall. Your question on derm and international. You were referencing Europe, where we have had some of that competition for a while, but international is quite broad, as you know, and I think the competitive dynamics are quite different in different markets.

As you think about even some of our top five markets, if you pull in, say, Brazil or Australia, in some of those markets, these are products that are sold almost like over the counter in retail stores, where the strategies are quite different. I think some of our competitors are positioned a little differently than us, as well as some of those pricing dynamics in some of those other markets. So yes, Europe might look a little bit more in some of the markets like the U.S., but as you get outside of Europe, those market dynamics are quite unique in certain large markets that are top five markets for us, such as, say, Brazil or Australia.

Thank you. There are no further questions in queue. I will now turn the call back over to CEO Kristin Peck for any additional or closing remarks.

Well, thanks, everyone, for joining us today. As always, we really appreciated your questions and your continued interest in Zoetis, and we look forward to keeping you updated at future conferences and seeing you again on the Q4 call next year. Thanks, everybody.

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Company Participants